Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - HFpEF

MedXY AI/MedXY News/Tag: HFpEF

MedXY News

EnglishTag

HFpEF

22 all articles · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial immunotherapy heart failure obesity atrial fibrillation cardiovascular risk Cardiology biomarkers clinical trials Hypertension oncology public health critical care artificial intelligence breast cancer Alzheimer's disease diabetes cardiovascular disease type 1 diabetes nutrition chronic kidney disease

Latest news

Tag

Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction

Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction

By MedXY|Jun 20, 2026

Unclassified pulmonary hypertension often reflects early-stage HFpEF linked to left heart and metabolic dysfunction, identifiable via dynamic right heart catheterization and metabolomics.

Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model

Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model

By MedXY|Jun 15, 2026

Elamipretide improved skeletal muscle force, titin phosphorylation, and atrophy in a HFpEF rat model, supporting cardiolipin stabilization as a promising mitochondrial-targeted strategy.

Elamipretide Restores Skeletal Muscle Performance in a HFpEF Rat Model by Stabilizing Mitochondria

Elamipretide Restores Skeletal Muscle Performance in a HFpEF Rat Model by Stabilizing Mitochondria

By MedXY|Jun 19, 2026

In a HFpEF rat model, Elamipretide improved muscle force, reduced titin abnormalities, and prevented atrophy, supporting cardiolipin stabilization as a potential strategy for exercise intolerance.

Can a Mitochondrial “Membrane Stabilizer” Restore Muscle Function in HFpEF? New Rat Data on Elamipretide

Can a Mitochondrial “Membrane Stabilizer” Restore Muscle Function in HFpEF? New Rat Data on Elamipretide

By MedXY|Jun 19, 2026

In a HFpEF rat model, elamipretide improved skeletal muscle force, reduced titin hyperphosphorylation, and prevented atrophy, supporting cardiolipin stabilization as a promising metabolic strategy.

Cardiolipin Stabilization Revives Skeletal Muscle Performance in a Preclinical HFpEF Model

Cardiolipin Stabilization Revives Skeletal Muscle Performance in a Preclinical HFpEF Model

By MedXY|Jun 19, 2026

In a rat model of HFpEF, the mitochondrial-targeted peptide elamipretide improved skeletal muscle force, reduced atrophy, and normalized titin phosphorylation, supporting cardiolipin stabilization as a promising mechanism.

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF

By MedXY|Jun 9, 2026

A Circulation study identifies SRPK3-mediated alternative splicing of TPM1 exon 9a as a driver of myofibrillar disarray, reduced myocardial compliance, and diastolic dysfunction in HFpEF, highlighting a potential disease-modifying therapeut

Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk

Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk

By MedXY|May 19, 2026

In FINEARTS-HF, EMPEROR-Preserved biomarker-based risk models showed good prognostic discrimination in HFmrEF/HFpEF, and finerenone’s relative treatment effect was consistent across the full baseline risk spectrum.

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial

By MedXY|May 12, 2026

In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

By MedXY|Apr 15, 2026

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over

Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity

Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity

By MedXY|Jan 17, 2026

The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

By MedXY|Dec 29, 2025

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY|Dec 26, 2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit exc

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY|Dec 26, 2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY|Dec 26, 2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and c

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY|Dec 4, 2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was

Decline in LVEF Predicts Ventricular Tachyarrhythmias and Mortality in HFpEF: Insights from the CHART-2 Study

Decline in LVEF Predicts Ventricular Tachyarrhythmias and Mortality in HFpEF: Insights from the CHART-2 Study

By MedXY|Oct 6, 2025

A mild-to-significant decline in left ventricular ejection fraction (LVEF) in heart failure with preserved ejection fraction (HFpEF) signals higher risks of lethal arrhythmias, sudden cardiac death, and mortality, underscoring the need for

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY|Oct 5, 2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Unraveling Heart-Lung Interactions in HFpEF: The Impact of Dynamic Hyperinflation on Exercise Pulmonary Capillary Wedge Pressure

Unraveling Heart-Lung Interactions in HFpEF: The Impact of Dynamic Hyperinflation on Exercise Pulmonary Capillary Wedge Pressure

By MedXY|Oct 4, 2025

Exercise-induced dynamic hyperinflation in HFpEF patients is linked to elevated pulmonary capillary wedge pressure, suggesting altered lung mechanics contribute significantly to exercise intolerance beyond ventricular stiffness alone.

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

Untangling Adiposity and Insulin Resistance in HFpEF: Clarifying Their Distinct Impact on Cardiac Function

By MedXY|Oct 4, 2025

This study reveals that excess adiposity, rather than insulin resistance or diabetes, predominantly drives left heart abnormalities and elevated pulmonary pressures in HFpEF, highlighting the need for targeted cardiometabolic therapies beyo

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY|Oct 3, 2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Ask MedXY AI

Most popular

Clinical Updates

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

Family Medicine & Nutrition

The Curious Scent of Feces: The Dual Identity and Health Secrets of Skatole

Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Family Medicine & Nutrition

How Often Should Men Have Sex? Harvard Study Links 21 Times a Month to Lower Prostate Cancer Risk

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications